The Possible Clinical Beneficial Effects of Atorvastatin in Iraqi Patients with Systolic Heart Failure

Abstract

This study was designed to evaluate the therapeutic effectiveness of atorvastatin in Iraqi patients with systolic heart failure. Sixty heart failure patients were participated in this study and their ages ranged from (35-72) years. The patients were divided into three groups: patients with heart failure and normal lipid profile not receiving atorvastatin (group one), patients with heart failure and normal lipid profile receiving atorvastatin (group two), patients with heart failure and dyslipidemia receiving atorvastatin. Twenty healthy subjects were selected to be a normal group for the purpose of comparison. Several parameters of inflammation and oxidative stress (hs-CRP, TNF-#x3B1;, total antioxidant status and adiponectin) as well as left ventricular ejection fraction were measured. The study duration was three months and the parameters were measured at baseline, one-half month and three months. The results showed that the serum level of hs-CRP, TNF-#x3B1; and total antioxidant status were not significantly changed in group one patients, while they were significantly changed in the other two groups. The seum level of adiponectin was not significantly changed in any of the three groups. The LVEF was significantly increased in the two groups who received atorvastatin, while it was not significantly changed in grouop one patients.